M2
528 Results
Advanced Search
Showing
Narrow Your Results Use the filters below to refine your search
By Application
By Industry
-
-
Optimization and Process Simulation | Ultrafiltration Learning Center | Biopharmaceutical Manufacturing | MilliporeSigma
Before you implement an ultrafiltration step, define these key operation parameters: Crossflow rate, Transmembrane pressure (TMP), Filtrate control, Membrane area and Diafiltration design. -
Activated Carbon Tutorial | Water Purification | MilliporeSigma
Activated carbon is made of organic material porous particulates containing a maze of small pores, which account for the substance's highly developed surface. -
Press Release: MilliporeSigma Introduces Parteck® SLC, Silica-based Excipient for Enhanced Drug Solubility and Bioavailability
MilliporeSigma, today introduced Parteck® SLC, a new excipient with a unique surface structure that delivers significantly increased loadability for active pharmaceutical ingredients (API). -
LiChrosorb® HPLC Columns and Sorbents | Analytics and Sample Preparation | MilliporeSigma
LiChrosorb® HPLC packing materials consist of fully porous irregular particles available as analytical or semi-preparative LiChroCART® and Hibar® RT columns. -
LiChrosorb® RP-18 (5 µm) | Analytical and Sample Preparation | MilliporeSigma
LiChrosorb® RP-18 (5 µm) columns and sorbents for reversed-phase HPLC are classified as L1 columns, fully compliant with US Pharmacopoeia specifications. -
Press Release: MilliporeSigma Receives Recertification of GMP Compliance for Biodevelopment Centre in Martillac, France
MilliporeSigma, today announced that its Biodevelopment Centre in Martillac, France, has been recertified by the French National Agency for Medicines and Health Products Safety (ANSM), the competent authority of France. -
Preclinical | Emerging Biotech | MilliporeSigma
Pre-clinical testing establishes that the target compound is safe and effective - before it can be tested in humans. -
Phase III | Emerging Biotech | MilliporeSigma
Phase III trials use a much larger patient population - in the thousands - to give statistical weight to results that can prove safety and efficacy. -
Phase I | Emerging Biotech | MilliporeSigma
Phase I means you've filed your IND and are ready to begin evaluating your drug in humans.